T-bet is essential for Th1-mediated, but not Th17-mediated, CNS autoimmune disease

Citation for published version:
O'connor, RA, Cambrook, H, Huettner, K & Anderton, SM 2013, 'T-bet is essential for Th1-mediated, but not Th17-mediated, CNS autoimmune disease', European Journal of Immunology, vol. 43, no. 11, pp. 2818-2823. https://doi.org/10.1002/eji.201343689

Digital Object Identifier (DOI):
10.1002/eji.201343689

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
European Journal of Immunology

Publisher Rights Statement:
© 2013 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co. KGaA Weinheim.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
T-bet is essential for Th1-mediated, but not Th17-mediated, CNS autoimmune disease

Richard A. O’Connor, Helen Cambrook, Katja Huettner and Stephen M. Anderton

Medical Research Council Centre for Inflammation Research, Centre for Multiple Sclerosis Research and Centre for Immunity Infection and Evolution, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK

T cells that produce both IL-17 and IFN-γ, and co-express ROR-γt and T-bet, are often found at sites of autoimmune inflammation. However, it is unknown whether this co-expression of T-bet with ROR-γt is a prerequisite for immunopathology. We show here that T-bet is not required for the development of Th17-driven experimental autoimmune encephalomyelitis (EAE). The disease was not impaired in T-bet⁻/⁻ mice and was associated with low IFN-γ production and elevated IL-17 production among central nervous system (CNS) infiltrating CD4⁺ T cells. T-bet⁻/⁻ Th17 cells generated in the presence of IL-6/TGF-β/IL-1 and IL-23 produced GM-CSF and high levels of IL-17 and induced disease upon transfer to naïve mice. Unlike their WT counterparts, these T-bet⁻/⁻ Th17 cells did not exhibit an IL-17→IFN-γ switch upon reencounter with antigen in the CNS, indicating that this functional change is not critical to disease development. In contrast, T-bet was absolutely required for the pathogenicity of myelin-responsive Th1 cells. T-bet-deficient Th1 cells failed to accumulate in the CNS upon transfer, despite being able to produce GM-CSF. Therefore, T-bet is essential for establishing Th1-mediated inflammation but is not required to drive IL-23-induced GM-CSF production, or Th17-mediated autoimmune inflammation.

Keywords: EAE · T-bet · T cells · Th1 · Th17

See accompanying article by Grifka-Walk et al. and commentary by Spath and Becher

Additional supporting information may be found in the online version of this article at the publisher’s web-site

Introduction

An illuminating series of studies over the past 5 years has led to the appreciation that, far from being members of categorically fixed subsets, CD4⁺ T cells can switch their expression of transcription factors and therefore downstream effector functions including cytokines, dependent on the inflammatory environment they find themselves in [1]. An excellent pathological example of this T-cell plasticity comes from the study of the CD4⁺ T-cell population that drives experimental autoimmune encephalomyelitis (EAE) in the mouse central nervous system (CNS). Observations that this cardinal “Th1-driven” disease was independent of either IFN-γ or IL-12 [2, 3], led to the appreciation of the indispensable role of IL-23 [4] and, ultimately, to the characterization of the IL-17-producing, ROR-γt-expressing, Th17 subset and its importance in EAE [5]. This fits with data from cytokine-deficient mice revealing that, as well as IL-23 and ROR-γt, both IL-6 and IL-1 (important factors in Th17 differentiation) are indispensable for
EAE [5, 6]. Nevertheless, interrogation of the T-cell infiltrate in the CNS commonly reveals strong production of IFN-γ and expression of the Th1-master regulator T-bet. Moreover, T-bet has been reported to be essential for EAE [7], even in passive transfer models involving administration of myelin-reactive Th17 cells [8]. This paradox has been resolved by elegant fate-mapping studies that revealed that the majority IFN-γ+ and T-bet+ T cells in the CNS have previously expressed, but since extinguished, IL-17 [9, 10].

The reported requirement for T-bet in EAE, whether driven by Th1 or Th17 populations, promotes this transcription factor as a potential alternative therapeutic target, beyond individual T-cell-derived cytokines. In light of this, we sought to better understand the role of T-bet in EAE, starting with the hypothesis that it would have a key role in promoting or maintaining GM-CSF, which has recently come to the fore as an essential product of pathogenic T cells [11, 12]. We report that, while T-bet is required for the IL-17→IFN-γ switch, this is not required for EAE development.

Results and discussion

**T-bet is not required for the development of autoimmune CNS inflammation**

T-bet−/− mice developed EAE after immunization with the myelin oligodendrocyte glycoprotein 35–55 peptide (pMOG). While there was consistently a delay in disease onset in the absence of T-bet (Fig. 1A), the peak severity of disease did not differ significantly between WT and T-bet−/− mice. IFN-γ was reduced (but not totally absent) in T-bet−/− T cells in the CNS (Fig. 1B). In contrast, IL-17 production was markedly elevated in the absence of T-bet (Fig. 1B). As described in earlier fate-mapping studies [9, 10], IFN-γ+ CNS T cells were almost entirely IL-17-negative by the peak of disease in WT mice. In contrast, the fewer IFN-γ+ T cells in T-bet−/− mice were mainly also IL-17+. The frequencies of GM-CSF+ CD4+ cells in the CNS did not differ between WT and T-bet−/− mice (Fig. 1B, lower panels).

Recall responses to pMOG (Fig. 1C–H) showed reduced (but not totally absent) IFN-γ, but elevated IL-17 from T-bet−/− splenocytes. Dynamic changes in levels of IFN-γ production were evident over time in WT mice, whereas IFN-γ production remained at a low level in T-bet−/− mice. Thus, at 10 days after priming, IFN-γ production was high in WT, but greatly impaired in T-bet−/− splenocytes (Fig. 1C), but by 21 days WT and T-bet−/− splenocytes produced equivalent (low) levels of IFN-γ (Fig. 1F). Again, GM-CSF production was not impaired in T-bet−/− mice (Fig. 1E and H).

We conclude that encephalitogenicity does not require T-bet and that this might reflect maintained GM-CSF and/or enhanced IL-17 production in its absence.

**Pathogenicity of autoreactive Th1 cells is T-bet dependent**

Th1 cells, generated from naive T cells that have not passed through the IL-17-producing stage that occurs in vivo after immunization, can induce EAE and also produce GM-CSF [11, 12]. We therefore asked whether T-bet−/− T cells exposed to Th1-promoting conditions (IL-12 and IL-18) would maintain GM-CSF production and pathogenic function.

We first generated T cells for passive transfer from LNs of H-2b mice that have been immunized with pMOG (Fig. 2A). WT IL-12-conditioned cells transferred robust EAE, whereas T-bet−/− cells did not transfer disease (Fig. 2B). At the time of their transfer, WT IL-12-conditioned cells produced IFN-γ with very few staining for IL-17. In their T-bet−/− counterparts, this pattern was reversed (Fig. 2C). The transferred T-bet−/− cells seemed able to persist in the spleen as indicated by a strong production of IL-17 upon pMOG recall (while IFN-γ and GM-CSF production were reduced,

© 2013 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co. KGaA Weinheim.

www.eji-journal.eu
but not absent), compared to spleens of mice receiving WT cells (Fig. 2D–F). The failure of IL-12-conditioned T-bet−/− cells to drive EAE correlated with an inability to migrate to (or expand in) the CNS as evidenced by poor representation of CD4+ or MHC-II+ CD11b+ cells in the CNS (Fig. 2G and H).

Using a second system, in which Th1 cells are generated from naive myelin basic protein (MBP) responsive Tg4 TCR transgenic T cells by MBP peptide stimulation in the presence of IL-12 and IL-18 (Fig. 2I), we also found that passive EAE was dependent on expression of T-bet in the transferred T cells (Fig. 2J). At the time of transfer, the frequency of IFN-γ+ cells was reduced (but not absent) in Tg4.Tbet−/− Th1 cells (Fig. 2K). The lack of a profound increase in IL-17 expression by these cells (Fig. 2K) differed from the elevated IL-17 that was seen in pMOG-immunized T-bet−/− cells (Fig. 1B, D, and G), even after in vitro exposure to IL-12 (Fig. 2C). This difference is likely to reflect exposure to IL-17-promoting factors (IL-1, IL-6, and IL-23) during in vivo priming of T-bet−/− mice, but not during the in vitro polarization of Th1 cells from naive Tg4.T-bet−/− cells. GM-CSF production was not impaired in Tg4.Tbet−/− Th1 cells (Fig. 2L). Again, lack of disease reflected an inability of the transferred Tg4.Tbet−/− Th1 cells to accumulate in the CNS and their retention in the spleen (Fig. 2M–O).

Pathogenicity of autoreactive Th17 cells is T-bet independent

The phenotype of the T-bet−/− CNS T cells in active EAE (Fig. 1B) suggested a population of stable Th17 cells. We therefore generated Th17-polarized cells and tested their requirement for T-bet to induce EAE (Fig. 3). IL-23-conditioned T cells from pMOG-primed LNs of T-bet−/− mice had high-IL-17 production and both WT and T-bet−/− cultures showed strong expression of GM-CSF at the time of transfer (data not shown) and were equally encephalitogenic, providing indistinguishable clinical courses (Fig. 3B). We also generated Th17 cells from naive Tg4 T cells (Fig. 3C) and again found that WT and T-bet−/− Tg4 cells were equally encephalitogenic (Fig. 3D). Consistent with the paradigm in which IL-17+ T cells begin to express T-bet, extinguish IL-17, and switch-on IFN-γ production over the course of EAE, Tg4.WT Th17 cells had limited IFN-γ production at the time of transfer, but had gained this function and were IL-17-negative when retrieved from the CNS (Fig. 3E and F). This shift in function did not occur in Tg4.T-bet−/− Th17 cells (Fig. 3G and H).
Pathogenicity of Th17 cells is T-bet independent. (A and B) EAE was induced in C57BL/6 mice by passive transfer of WT or T-bet\(^{-/-}\) IL-23-conditioned cells derived from the draining LNs of pMOG-immunized mice. (B) Clinical course of disease is shown. Results are from one experiment representative of two independent experiments with \(n = 5\) per group per experiment. Data are shown as mean ± SEM. (C-G) EAE was induced in B10.PLxC57BL6 mice by passive transfer of Th17-polarized Tg4.WT or Tg4.T-bet\(^{-/-}\) T cells. (D) Clinical course of disease is shown. Results are from one experiment representative of two independent experiments with 5–11 mice per group per experiment. Data are shown as mean ± SEM. (E-G) Flow cytometric analysis of cytokine production and transcription factor expression in Tg4.WT and Tg4.T-bet\(^{-/-}\) Th17 cells at the time of transfer and after retrieval from the inflamed CNS at 19 days posttransfer. (E) IL-17 versus IFN-\(\gamma\) production, (F) individual cytokines, and (G) T-bet and ROR-\(\gamma\)t (G: gray histograms show isotype control staining).

Cells. Their IL-17 production was maintained in the CNS, with no evidence for IFN-\(\gamma\) production (Fig. 3E and F).

Not only was T-bet required for the gain of IFN-\(\gamma\) production, it was also necessary for the loss of IL-17 production by cells retrieved from the CNS (Fig. 3E and F). This is consistent with the CNS CD4\(^{+}\) cytokine profiles displayed by WT versus T-bet\(^{-/-}\) mice during pMOG-induced active EAE (Fig. 1B). There are two possible T-cell-intrinsic mechanisms for the loss of IL-17 production when T-bet is present: (i) via the interaction of T-bet with runx1 preventing runx1-mediated transactivation of the Rorc promoter [13]; (ii) by boosting IFN-\(\gamma\) production which in turn inhibits IL-17 production [14]. Fitting with either scenario, whereas ROR-\(\gamma\)t expression was lost in WT Th17 cells retrieved from the CNS, at least some of their T-bet\(^{-/-}\) counterparts maintained ROR-\(\gamma\)t to pretransfer levels (Fig. 3G).

We have found no evidence for an impairment of proliferative capacity in T-bet\(^{-/-}\) T cells (data not shown), so we believe that the absence of transferred T-bet\(^{-/-}\) Th1 cells from the CNS most likely reflects a failure in migration. Expression of CCR6, which has been proposed to facilitate Th17 cell entry into the CNS (reviewed in [15]), was not affected by the lack of T-bet in Tg4 Th17 cells (data not shown). As would be expected, T-bet deficiency did impair expression of Th1-associated CXCR3 in Th1-polarized Tg4 cells (data not shown). However, we cannot currently conclude that this accounts for the inability of T-bet\(^{-/-}\) IL-12-conditioned or Th1 cells to enter the CNS, because there is no consensus on the importance of CXCR3 expression for Th1-induced EAE [15]. The molecular basis for the failure of T-bet\(^{-/-}\) Th1 cells to accumulate in the CNS therefore remains to be provided.

Our data differ significantly from those recently reported by Duhen et al. [16]. That report reasserted that mice with global T-bet deficiency are resistant to EAE and implied possible necessary roles for T-bet expression by non-T cells. We show that this is not the case. Duhen et al. [16] used mice in which T-bet-deficiency was controlled by the CD4 promoter and showed the same delayed course of EAE that we see here with T-bet\(^{-/-}\) mice. That report also concluded that the ability to produce IFN-\(\gamma\) co-associated with pathogenic function of Th17 cells, even in the absence of T-bet. Here, we show that, in the absence of T-bet, Th17 cells can drive EAE without the development of IFN-\(\gamma\) production. Subtle differences in approach between the two studies might account for these discrepancies. For example, Duhen et al. [16] used chronic in vitro stimulation with IL-23 to engender IFN-\(\gamma\) production by T-bet\(^{-/-}\) Th17 cells. In contrast, our Th17 cells were wholly capable of pathogenic function without such extended in vitro manipulation. However, the study by Duhen et al. does concur with ours in the conclusion that T-bet is not critically involved in GM-CSF production by pathogenic T cells.

Concluding remarks

There is an absolute requirement for the putative pathogenic T cell in EAE to be sensitive to IL-6, IL-23, and IL-1 and to produce GM-CSF. Our data, combined with those of others [11, 12],
indicate that there is no gross deficiency in these critical features in the absence of T-bet. Based on this, Th17-driven inflammation should be unimpaired in T-bet<sup>−/−</sup> mice. This is what we find here. While increased T-bet expression is certainly a characteristic of pathogenic Th17 cells [17], we have shown definitively that it is entirely nonessential for EAE development and that Th17 cells can induce inflammatory pathology without co-opting those elements of the Th1 transcriptional program under the control of T-bet. Thus, T-bet may be a less attractive therapeutic target than it has previously appeared.

**Materials and methods**

**Mice, antigens, and tissue culture medium**

C57BL/6, Tg4.CD45.1 (Tg4.WT) [18], T-bet<sup>−/−</sup> (obtained from The Jackson Laboratory), and B10.PLxC56BL/6 mice were bred under specific pathogen-free conditions at the University of Edinburgh. T-bet<sup>−/−</sup> mice were crossed with Tg4.CD45.1 mice to generate Tg4.T-bet<sup>−/−</sup> mice. All experiments were approved by the University of Edinburgh ethical review committee and were performed in adherence to UK legislation. Mice were screened in-house, using the Jackson Labs protocol to confirm knockout status and independently by Transnetx Inc. (Cordova, TN, USA). pMOG (MEVGWYRSPFSRVVHLYRNNGK) and the MBP Ac1–9 (Ac-ASQKRPSQR) peptide were synthesized by Cambridge Research Biochemicals (Cleveland, UK). Tissue culture medium was RPMI 1640 medium, supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and 5 × 10<sup>−6</sup> M 2-ME (all from Invitrogen Life Technologies, Paisley, UK), and 10% FCS (Sigma, Poole, UK).

**Active induction of EAE**

EAE was induced in H-2<sup>−</sup> (C57BL/6 and T-bet<sup>−/−</sup>) mice using 100 μg of pMOG<sub>35–55</sub> peptide emulsified in CFA, as described previously [19]. Clinical signs of EAE were assessed daily with the following scoring system: 0, no signs; 1, flaccid tail; 2, impaired righting reflex and/or gait; 3, partial hind limb paralysis; 4, total hind limb paralysis; 5, hind limb paralysis with partial front limb paralysis; 6, moribund or dead. Assessment of CNS (brain and spinal cord) immune cells was as described previously [20].

**Adoptive transfer of EAE**

pMOG-reactive cells were generated from draining LN cells 10 days after immunization with pMOG<sub>35–55</sub> and cultured at 4 × 10<sup>6</sup> cells/mL in the presence of 10 μg/mL pMOG. pMOG-reactive IL-12 conditioned cells [20], or IL-23 conditioning cells [21], were prepared as previously described.

Tg4 splenocytes were cultured at 4 × 10<sup>6</sup> cells/mL with 10 μg/mL MBP (Ac1–9). Conditions for Th1 polarization [20] and Th17 polarization [22] were as previously described. In all transfer experiments, 4 × 10<sup>6</sup> blasts were injected into WT recipients. Clinical signs of EAE were assessed as described above.

**Antibodies and flow cytometry analysis**

Cells were stained for flow cytometry using the indicated Abs. Intracellular staining for cytokines and transcription factors was performed as previously described [20]. Flow cytometry data were collected on a Fortessa flow cytometer (BD Biosciences) and all data were analyzed using FlowJo software (Tree Star, CA, USA).

**In vitro restimulation and cell culture**

A total of 8 × 10<sup>5</sup> splenocytes per well (in flat-bottom 96-well microtiter plates) were cultured in X-VIVO-15<sup>TM</sup> tissue culture medium (BioWhittaker, Wokingham, UK) and stimulated with a dose range of pMOG. After 72-h culture, supernatants were removed for determination of cytokine levels by ELISA.

**Statistical analysis**

Flow cytometry data were compared by unpaired t-test. ELISA data were compared using two-way ANOVA with Bonferroni posttesting.

Acknowledgements: This work was supported by grants from the UK Medical Research Council and the Wellcome Trust to SMA.

Conflict of interest: The authors declare no financial or commercial conflict of interest.

**References**

1 Vahedi, G., A. C. P., Hand, T. W., Laurence, A., Kanno, Y., O’Shea, J. J. and Hirahara, K., Helper T-cell identity and evolution of differential transcriptomes and epigenomes. *Immunol. Rev.* 2013. 252: 24–40.

2 Becher, B., Durell, B. G. and Noelle, R. J., Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. *J. Clin. Invest.* 2002. 110: 493–497.

3 Ferber, I. A., Brocke, S., Taylor-Edwards, C., Ridgway, W., Dinisco, C., Steinman, L., Dalton, D. et al., Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). *J. Immunol.* 1996. 156: 5–7.

4 Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L. et al., Interleukin-23 rather than interleukin-12 is the critical
cytokine for autoimmune inflammation of the brain. Nature 2003. 421: 744–748.

5 Korn, T., Bettelli, E., Oukka, M. and Kuchroo, V. K., IL-17 and Th17 cells. Annu. Rev. Immunol. 2009. 27: 485–517.

6 Sutton, C., Breerenton, C., Keogh, B., Mills, K. H. and Lavelle, E. C., A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 2006. 203: 1685–1691.

7 Bettelli, E., Sullivan, B., Szabo, S. J., Sobel, R. A., Glimcher, L. H. and Kuchroo, V. K., Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J. Exp. Med. 2004. 200: 79–87.

8 Gocke, A. R., Cravens, P. D., Ben, L. H., Hussain, R. Z., Northrop, S. C., Racke, M. K. and Lovett-Racke, A. E., T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J. Immunol. 2007. 178: 1341–1348.

9 Kurschus, F. C., Croxford, A. L., Heinen, A. P., Wortge, S., Ielo, D. and Waisman, A., Genetic proof for the transient nature of the Th17 phenotype. Eur. J. Immunol. 2010. 40: 3336–3346.

10 Hirotta, K., Duarte, J. H., Veldhoen, M., Hornsby, E., Li, Y., Cua, D. J., Ahlfors, H. et al., Fate mapping of IL-17-producing T cells in inflammatory responses. Nat. Immunol. 2011. 12: 255–263.

11 Codarri, L., Gyulveszi, G., Tosevski, V., Hesske, L., Fontana, A., Mangentat, L., Suter, T. et al., RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 2011. 12: 560–567.

12 El-Behi, M., Ciric, B., Dai, H., Yan, Y., Cullimore, M., Safavi, F., Zhang, G. X. et al., The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 2011. 12: 568–575.

13 Lazarevic, V., Chen, X., Shim, J. H., Hwang, E. S., Jang, E., Bolm, A. N., Oukka, M. et al., T-bet represses T(H)17 differentiation by preventing Runx1-mediated activation of the gene encoding RORgammat. Nat. Immunol. 2010. 12: 96–104.

14 Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M. and Weaver, C. T., Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005. 6: 1123–1132.

15 Prendergast, C. T. and Anderton, S. M., Immune cell entry to central nervous system–current understanding and prospective therapeutic targets. Endocr. Metab. Immune Disord. Drug Targets 2009. 9: 315–327.

16 Duhon, R., Glatigny, S., Arbelaez, C. A., Blair, T. C., Oukka, M. and Bettelli, E., Cutting edge: the pathogenicity of IFN-gamma-producing Th17 cells is independent of T-bet. J. Immunol. 2013. 190: 4478–4482.

17 Lee, Y., Awasthi, A., Yosef, N., Quintana, F. J., Xiao, S., Peters, A., Wu, C. et al., Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 2012. 13: 991–999.

18 O’Connor, R. A., Leech, M. D., Suffner, J., Hammerling, G. J. and Anderton, S. M., Myelin-reactive, TGF-beta-induced regulatory T cells can be programmed to develop Th1-like effector function but remain less proinflammatory than myelin-reactive Th1 effectors and can suppress pathogenic Th1 cell clonal expansion in vivo. J. Immunol. 2010. 185: 7235–7243.

19 Leech, M. D., Barr, T. A., Turner, D. G., Brown, S., O’Connor, R. A., Gray, D., Mellanby, R. J. et al., Cutting edge: IL-6-dependent autoimmune disease: dendritic cells as a sufficient, but transient, source. J. Immunol. 2013. 190: 881–885.

20 O’Connor, R. A., Prendergast, C. T., Sabatos, C. A., Lau, C. W., Leech, M. D., Wraith, D. C. and Anderton, S. M., Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 2008. 181: 3750–3754.

21 Kroenke, M. A., Carlson, T. J., Andjelkovic, A. V. and Segal, B. M., IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 2008. 205: 1535–1541.

22 Jager, A., Dardalhon, V., Sobel, R. A., Bettelli, E. and Kuchroo, V. K., Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J. Immunol. 2009. 183: 7169–7177.

Abbreviation: MBP: myelin basic protein

Full correspondence: Prof. Stephen M. Anderton, Centre for Inflammation Research, Queen’s Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4JL, United Kingdom
Fax: +44-131-242-6560
e-mail: steve.anderton@ed.ac.uk

See accompanying article: http://dx.doi.org/10.1002/eji.201343723

See accompanying commentary: http://dx.doi.org/10.1002/eji.201344109

Received: 8/5/2013
Revised: 14/6/2013
Accepted: 17/7/2013
Accepted article online: 23/7/2013